Drug Profile
Research programme: regenerative hearing therapeutics - Sound Pharmaceuticals
Alternative Names: SPI 128; SPI 5505; SPI-5557Latest Information Update: 01 Jun 2022
Price :
$50
*
At a glance
- Originator Sound Pharmaceuticals
- Class
- Mechanism of Action Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Sensorineural hearing loss
Most Recent Events
- 01 Jun 2022 Regenerative hearing therapeutics is still in preclinical development for Sensorineural hearing loss in USA (Sound Pharmaceuticals pipeline, June 2022)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Sensorineural hearing loss in USA (Parenteral, Injection)
- 18 Jul 2016 Preclinical development is ongoing (Sound Pharmaceuticals pipeline, July 2016)